Literature DB >> 9129893

Problems encountered during introduction of Gianturco coils for transcatheter occlusion of the patent arterial duct.

O Galal1, M de Moor, F Fadley, S Qureshi, S Naffa, S Oufi, M Suhl, F Abbag, A A Schmaltz.   

Abstract

OBJECTIVE: To define the problems encountered during transcatheter occlusion of the patent arterial duct using Gianturco coils.
METHODS: Between January 1994 and November 1995, 93 patients were admitted in whom it was intended to occlude the patent arterial duct using Gianturco coils. Anterograde transcatheter coil occlusion was performed via the femoral vein in 81 patients. In the remaining 12 the procedure was done via the femoral artery.
RESULTS: Coils were implanted successfully in 82/93 (88%) patients. In 11 patients the procedure was a failure. In 19/93 patients (20%), inadvertent embolization of the coil occurred. The coils were retrieved in all except one patient. In 17 of these patients, new coils were then reimplanted successfully. Doppler echocardiography after the procedure showed that in 9/82 (11%) patients the left pulmonary artery Doppler peak velocity exceeded 1.5 m.s-1 (mean 1.2 m.s-1) raising concern about left pulmonary artery branch stenosis. The complete occlusion rate at discharge from hospital was 72/82 (88%). Follow-up ranges from 1 day to 14 months (mean 2/12 months) in the 82 patients in whom successful deployment of coils was possible. In two patients, the arterial duct became occluded at follow-up. One additional patient had complete occlusion after reocclusion using another coil. Thus, after short-term follow-up a total of 75/82 patients (91.4%) have a completely occluded arterial duct after coil implantation.
CONCLUSION: Transcatheter occlusion of the patent arterial duct using Gianturco coils is an effective and safe technique. In the learning curve there is a relatively high rate of inadvertent embolization, but the coils can be retrieved in the vast majority of patients. The complication rate is offset by the high early occlusion rate and the inexpensiveness of the procedure.

Entities:  

Mesh:

Year:  1997        PMID: 9129893     DOI: 10.1093/oxfordjournals.eurheartj.a015307

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

1.  Safe retrieval of embolized patent ductus arteriosus coil via left thoracotomy.

Authors:  Melanie Finkbeiner; Jacques Leblanc; Martin Hosking; Andrew Campbell
Journal:  Exp Clin Cardiol       Date:  2010

2.  Transcatheter occlusion of the patent ductus arteriosus: a comparison of two devices.

Authors:  M K El Mallah; A J Sands; F A Casey; B G Craig; H C Mulholland
Journal:  Ir J Med Sci       Date:  2002 Jul-Sep       Impact factor: 1.568

3.  Transcatheter device closure of patent ductus arteriosus without arterial access--single institution experience.

Authors:  Gaurav Garg; Anurakti Srivastava; Himanshu Tyagi; Sridhar P Reddy; Anil Sivadasan Radha
Journal:  Indian Heart J       Date:  2013-08-31

Review 4.  [Interventions in congenital heart disease and their sequelae in adults].

Authors:  A A Schmaltz; U Neudorf; S Sack; O Galal
Journal:  Herz       Date:  1999-06       Impact factor: 1.443

5.  Complications after transcatheter closure of patent ductus arteriosus.

Authors:  Gi Young Jang; Chang Sung Son; Joo Won Lee; Jae Young Lee; Soo Jin Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

6.  Preclosure pressure gradients predict patent ductus arteriosus patients at risk for later left pulmonary artery stenosis.

Authors:  Srinath T Gowda; Shelby Kutty; Makram Ebeid; Athar M Qureshi; Sarah Worley; Larry A Latson
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

7.  Cost-effectiveness analysis of different devices used for the closure of small-to-medium-sized patent ductus arteriosus in pediatric patients.

Authors:  Sonia A El-Saiedi; Amal M El Sisi; Rodina Sobhy Mandour; Doaa M Abdel-Aziz; Wael A Attia
Journal:  Ann Pediatr Cardiol       Date:  2017 May-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.